Advaxis Signs Agreement with Cobra For Manufacture of Lovaxin C Vaccine.

NORTH BRUNSWICK, N.J. -- Advaxis, Inc. (OTCBB: ADXS) has signed an agreement with UK based Cobra Biomanufacturing Plc (AIM: CBF) for the manufacturing of its Phase II clinical trial material of a therapeutic cervical cancer vaccine known as Lovaxin C.

John Rothman, Vice President, Clinical Development, said, "We look forward to continuing our relationship with Cobra as we move forward with the development of live Listeria vaccines for the treatment of cancer. Our initial clinical work demonstrated the real world utility of our concepts, and Cobra's ability to execute their production as potential cancer immunotherapeutic agents."

David Thatcher, CEO at Cobra, said, "We have been supporting the Advaxis Lovaxin C clinical program since 2003 and are delighted to extend our work with Advaxis on this exciting project."

About: Lovaxin C Vaccine

Based on over a decade of work in the laboratory of Dr. Yvonne Paterson at the University of Pennsylvania, the Company's broadly enabling Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Listeria has the ability to generate a robust immune response and produce an unusually strong and effective therapeutic immune response to existing cancers and other diseases affecting many related immune mechanisms simultaneously and in an integrated fashion. 'Advaxis' Listeria-based technology not only generates an unusually profound cytotoxic immune response capable of killing cancer cells, but the Company's proprietary antigen fusion protein technology minimizes the suppressive effects of regulatory T cells that appear to inhibit many vaccines, and also creates a local tumor environment conducive to the therapeutic effects of the activated tumor killing cells. Unlike current products on the market, which are ineffective in women already infected with HPV, which causes cervical cancer, Lovaxin C is designed to treat women who have already developed cervical cancer as a result of the HPV infection.

About Advaxis, Inc.

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes multiple simultaneous immunological mechanisms to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

About Cobra Biomanufacturing Plc

Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products. Cobra has developed a range of unique, patented technologies, which underpins a successful revenue generating contract manufacturing business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising PS7 million and raised a further PS5.2 million in May 2003 in order to further expand capacity in Oxford UK. Since floatation the Company has grown turnover from PS3 million to PS10 million providing expert manufacturing services across the world with over 80% of revenues currently from the US market.

www.cobrabio.com

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.